CAMBRIDGE, Mass. — Zai Lab Limited said President and Chief Operating Officer Josh Smiley will leave the company effective Friday, May 22, as part of senior leadership changes intended to strengthen operational performance and efficiency.
The company did not name an immediate successor.
“I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,” said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.
Zai Lab said it expects multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas. The company also expects a first-in-human data readout from the global Phase 1/1b study of ZL-1503, an IL-13/IL-31Rα therapy.
The company said it is also preparing for the launch of COBENFY in China, along with multiple anticipated regional regulatory approvals and expected data readouts.
Zai Lab is a commercial-stage biopharmaceutical company based in China and the United States. The company focuses on discovering, developing and commercializing medicines for areas including oncology, immunology, neuroscience and infectious disease.
